Acadia Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Acadia Pharmaceuticals (ACAD).

Price Target Range — 10 Quarters

Analyst Consensus — 21 Analysts

2S.Buy

15Buy

3Hold

1Sell

Consensus RatingBuy# Analysts21Avg. Consensus PT$31Upside to Avg. PT+57.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 8, 2026	RBC Capital	Brian Abrahams	PT Cut	Outperform	$37→$36
Sep 25, 2026	Deutsche Bank	David Hoang	PT Cut	Buy	$38→$31
Sep 25, 2026	HC Wainwright & Co.	Ananda Ghosh	PT Cut	Buy	$37→$33
Sep 25, 2026	Citizens	Jason N. Butler	PT Cut	Market Outperform	$36→$33
Sep 25, 2026	BMO Capital	Evan David Seigerman	PT Cut	Outperform	$36→$34
Sep 25, 2026	Needham	Ami Fadia	PT Cut	Buy	$41→$35
Sep 24, 2026	Citigroup	Yigal Nochomovitz	PT Cut	Buy	$40→$33
Sep 24, 2026	Needham	Ami Fadia	Maintained	Buy	$41
Aug 25, 2026	Deutsche Bank	David Hoang	PT Raise	Buy	$37→$38
Aug 25, 2026	Morgan Stanley	Jeffrey Hung	PT Raise	Equal-Weight	$27→$28
Aug 25, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$39→$40
Aug 17, 2026	UBS	Ashwani Verma	PT Raise	Buy	$45→$49
Aug 12, 2026	Needham	Ami Fadia	PT Raise	Buy	$38→$41
Aug 10, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$35→$39
Aug 5, 2026	Oppenheimer	Matthew Hershenhorn	PT Raise	Perform	$23→$25
Aug 5, 2026	RBC Capital	Brian Abrahams	PT Raise	Outperform	$36→$37
Aug 5, 2026	Citizens	Jason N. Butler	PT Raise	Market Outperform	$35→$36
Jul 21, 2026	Stifel	Paul Matteis	PT Raise	Hold	$24→$25
Jul 21, 2026	BMO Capital	Evan David Seigerman	PT Raise	Outperform	$34→$36
Jul 7, 2026	RBC Capital	Brian Abrahams	PT Raise	Outperform	$29→$36

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
RBC Capital Maintains Outperform on Acadia Pharmaceuticals, Lowers Price Target to $36

RBC Capital analyst Brian Abrahams maintains Acadia Pharmaceuticals (NASDAQ:ACAD) with a Outperform and lowers the price target from $37 to $36.

Benzinga Newsdesk

PRO
Deutsche Bank Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $31

Deutsche Bank analyst David Hoang maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $38 to $31.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $33

HC Wainwright & Co. analyst Ananda Ghosh maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $37 to $33.

Benzinga Newsdesk

PRO
Citizens Maintains Market Outperform on ACADIA Pharmaceuticals, Lowers Price Target to $33

Citizens analyst Jason N. Butler maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Market Outperform and lowers the price target from $36 to $33.

Benzinga Newsdesk

PRO
BMO Capital Maintains Outperform on ACADIA Pharmaceuticals, Lowers Price Target to $34

BMO Capital analyst Evan David Seigerman maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperform and lowers the price target from $36 to $34.

Benzinga Newsdesk

PRO
Needham Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $35

Needham analyst Ami Fadia maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $41 to $35.

Benzinga Newsdesk

Acadia Pharmaceuticals Inc

Acadia Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
RBC Capital Maintains Outperform on Acadia Pharmaceuticals, Lowers Price Target to $36

PRO
Deutsche Bank Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $31

PRO
HC Wainwright & Co. Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $33

PRO
Citizens Maintains Market Outperform on ACADIA Pharmaceuticals, Lowers Price Target to $33

PRO
BMO Capital Maintains Outperform on ACADIA Pharmaceuticals, Lowers Price Target to $34

PRO
Needham Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $35

People Also Watch

People Also Watch

Acadia Pharmaceuticals Inc

Acadia Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRORBC Capital Maintains Outperform on Acadia Pharmaceuticals, Lowers Price Target to $36

PRODeutsche Bank Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $31

PROHC Wainwright & Co. Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $33

PROCitizens Maintains Market Outperform on ACADIA Pharmaceuticals, Lowers Price Target to $33

PROBMO Capital Maintains Outperform on ACADIA Pharmaceuticals, Lowers Price Target to $34

PRONeedham Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $35

People Also Watch

People Also Watch

PRO
RBC Capital Maintains Outperform on Acadia Pharmaceuticals, Lowers Price Target to $36

PRO
Deutsche Bank Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $31

PRO
HC Wainwright & Co. Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $33

PRO
Citizens Maintains Market Outperform on ACADIA Pharmaceuticals, Lowers Price Target to $33

PRO
BMO Capital Maintains Outperform on ACADIA Pharmaceuticals, Lowers Price Target to $34

PRO
Needham Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $35